{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:04:18Z","timestamp":1770523458848,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"DOI":"10.7759\/cureus.30017","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T09:13:57Z","timestamp":1665134037000},"source":"Crossref","is-referenced-by-count":2,"title":["An Analysis of Biologic Therapies in Patients With Asthma and Chronic Rhinosinusitis"],"prefix":"10.7759","author":[{"given":"Mitchell R","family":"Gore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia C","year":"2018","unstructured":"Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018, 12:1753466618810192. 10.1177\/1753466618810192","journal-title":"Ther Adv Respir Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz M","year":"2020","unstructured":"Metz M, Vadasz Z, Kocat\u00fcrk E, Gim\u00e9nez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020, 59:38-45. 10.1007\/s12016-020-08794-6","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob D","year":"2016","unstructured":"El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016, 50:84-96. 10.1007\/s12016-015-8490-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama Y","year":"2020","unstructured":"Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergol Int. 2020, 69:167-77. 10.1016\/j.alit.2020.01.004","journal-title":"Allergol Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert P","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, et al.. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020, 146:595-605. 10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2020.06.001","article-title":"Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis","volume":"40","author":"Eschenbacher W","year":"2020","unstructured":"Eschenbacher W, Straesser M, Knoeddler A, Li RC, Borish L. Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis. Immunol Allergy Clin North Am. 2020, 40:539-47. 10.1016\/j.iac.2020.06.001","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-021-01013-y","article-title":"Biologic therapies for allergic rhinitis and nasal polyposis","volume":"21","author":"Geng B","year":"2021","unstructured":"Geng B, Dilley M, Anterasian C. Biologic therapies for allergic rhinitis and nasal polyposis. Curr Allergy Asthma Rep. 2021, 21:36. 10.1007\/s11882-021-01013-y","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor MC","year":"2019","unstructured":"McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019, 199:433-45. 10.1164\/rccm.201810-1944CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation","volume":"9","author":"Eger K","year":"2021","unstructured":"Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation. J Allergy Clin Immunol Pract. 2021, 9:1194-200. 10.1016\/j.jaip.2020.10.010","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu Q","year":"2022","unstructured":"Wu Q, Zhang Y, Kong W, et al.. Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol. 2022, 183:279-88. 10.1159\/000519228","journal-title":"Int Arch Allergy Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0145561320964653","article-title":"The role of biologics in chronic rhinosinusitis with nasal polyps","volume":"100","author":"Patel GB","year":"2021","unstructured":"Patel GB, Peters AT. The role of biologics in chronic rhinosinusitis with nasal polyps. Ear Nose Throat J. 2021, 100:44-7. 10.1177\/0145561320964653","journal-title":"Ear Nose Throat J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw TM","year":"2020","unstructured":"Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020, 124:326-32. 10.1016\/j.anai.2019.12.001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2500\/105065899781367500","article-title":"Correlation of allergy and severity of sinus disease","volume":"13","author":"Ramadan HH","year":"1999","unstructured":"Ramadan HH, Fornelli R, Ortiz AO, Rodman S. Correlation of allergy and severity of sinus disease. Am J Rhinol. 1999, 13:345-7. 10.2500\/105065899781367500","journal-title":"Am J Rhinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02996522","article-title":"Outcome analysis of functional endoscopie sinonasal surgery for paediatric rhinosinusitis using the Lund-Mackay-Kennedy scoring system","volume":"51","author":"Dutt SN","year":"1999","unstructured":"Dutt SN, Haider-Ali A, Stewart M, Morrissey SM. Outcome analysis of functional endoscopie sinonasal surgery for paediatric rhinosinusitis using the Lund-Mackay-Kennedy scoring system. Indian J Otolaryngol Head Neck Surg. 1999, 51:16-20. 10.1007\/BF02996522","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1067\/mhn.2001.119324","article-title":"Determination of the \"incidental\" Lund score for the staging of chronic rhinosinusitis","volume":"125","author":"Ashraf N","year":"2001","unstructured":"Ashraf N, Bhattacharyya N. Determination of the \"incidental\" Lund score for the staging of chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2001, 125:483-6. 10.1067\/mhn.2001.119324","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman KR","year":"2019","unstructured":"Chapman KR, Albers FC, Chipps B, et al.. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019, 74:1716-26. 10.1111\/all.13850","journal-title":"Allergy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet J","year":"2021","unstructured":"Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021, 9:2702-14. 10.1016\/j.jaip.2021.01.011","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol J","year":"2022","unstructured":"Mullol J, Laidlaw TM, Bachert C, et al.. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. 2022, 77:1231-44. 10.1111\/all.15067","journal-title":"Allergy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/118355-an-analysis-of-biologic-therapies-in-patients-with-asthma-and-chronic-rhinosinusitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:33Z","timestamp":1707508173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/118355-an-analysis-of-biologic-therapies-in-patients-with-asthma-and-chronic-rhinosinusitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.30017","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}